New drug combo with radiation for children with midline brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new combination of medicines (temozolomide, anlotinib, and bemarituzumab) taken during radiation therapy for children with a type of brain tumor called diffuse midline glioma. The goal is to see if this approach can help improve outcomes compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 3 and 18 years old.
- They must have a confirmed diagnosis of diffuse midline glioma (a specific type of brain tumor).
- The tumor was not fully removed with surgery.
- They have not had any prior treatment (like chemotherapy or radiation) for this tumor.
- At least one tumor spot must be visible on an MRI or CT scan.
- Blood counts and liver/kidney function must be within the ranges the study requires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial compares standard radiation therapy versus radiation plus a chemotherapy medicine called temozolomide in people with a newly diagnosed low-grade (WHO grade II) brain glioma after surgery. It’s designed to see if adding temozolomide improves outcomes while managing side effects.
Hear when a new Maintenance Treatment of Diffuse Midline Gliomas in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.